Mulibrey Nanism – Comprehensive Medical Guide
Overview
Mulibrey nanism (MUL) is a rare, autosomal‑recessive disorder marked by severe growth restriction, distinctive facial features, and a hallmark predisposition to cardiomyopathy and pericardial disease. The condition was first described in the early 1980s in a small Finnish population, and the gene responsible—TRIM37—was identified in 2005. Because the mutation is inherited in a recessive pattern, the disease is most common in populations with a high degree of founder effect, such as certain Finnish and Swedish families.
- Who it affects: Both males and females; symptoms usually appear in early childhood.
- Prevalence: Approximately 1 in 1–2 million people worldwide. In Finland, the carrier frequency is about 1 in 250, giving a disease prevalence of roughly 1 in 150,000–200,000.1
- Age of onset: Growth failure is evident by the end of the first year of life; cardiac complications often emerge in the teen years or early adulthood.
Symptoms
Symptoms are variable, but most patients present with a recognizable constellation of findings. Below is a complete list with brief descriptions.
Growth‑related features
- Severe short stature: Adult height typically 120–135 cm (≈4–4.5 ft).
- Low birth weight: Often <2,500 g (5.5 lb).
- Proportional dwarfism: Limbs and trunk are reduced in size but maintain normal body proportions.
Facial & skeletal characteristics
- Triangular face: Broad forehead, deep-set eyes, and a pointed chin.
- Prominent ears and long philtrum.
- Small hands and feet.
- Joint contractures: Particularly at the elbows and knees.
- Spine abnormalities: Scoliosis or thoracic kyphosis in up to 30% of patients.
Cardiac involvement
- Restrictive cardiomyopathy: Thickened ventricular walls with impaired filling.
- Pericardial constriction: Fibrotic thickening of the pericardium causing reduced cardiac output.
- Arrhythmias: Atrial fibrillation or ventricular tachycardia may appear in later stages.
- Heart failure: Symptoms such as shortness of breath, exercise intolerance, and peripheral edema.
Abdominal & hepatic findings
- Hepatomegaly and hepatic fibrosis: Seen in 40–60% of patients.
- Fatty liver disease (steatosis).
Metabolic & endocrine abnormalities
- Insulin resistance & early‑onset type 2 diabetes.
- Low serum IGF‑1 levels.
- Hypothyroidism: Documented in up to 15% of cases.
Other organ systems
- Renal anomalies: Mild tubular dysfunction or structural abnormalities.
- Ocular findings: Cataracts or retinal pigmentary changes in rare cases.
- Neurologic: Normal intelligence in most patients, although learning difficulties have been reported due to chronic illness.
Causes and Risk Factors
Mulibrey nanism is caused by loss‑of‑function mutations in the TRIM37 gene located on chromosome 17q22–23. TRIM37 encodes a ubiquitin‑E3 ligase involved in peroxisomal function and cellular stress responses. When the protein is absent or non‑functional, abnormal tissue growth, fibrosis, and metabolic derangements develop.
Inheritance pattern
- Autosomal recessive: Both parents must carry one defective copy of the gene. Carrier parents are typically asymptomatic.
- Consanguinity: Increases risk because relatives are more likely to share the same pathogenic allele.
Risk factors
- Being born into a family with a known TRIM37 mutation.
- Having Finnish, Swedish, or other Nordic ancestry where the founder mutation is more common.
- Consanguineous marriage (first‑cousin or closer).
Diagnosis
Because Mulibrey nanism is rare, diagnosis often follows a multidisciplinary work‑up involving genetics, cardiology, and endocrinology.
Clinical evaluation
- Detailed birth and family history (looking for consanguinity or affected relatives).
- Physical examination focusing on stature, facial features, joint contractures, and cardiac signs (e.g., elevated jugular venous pressure).
Imaging and functional tests
- Echocardiogram: Detects restrictive cardiomyopathy, pericardial thickening, and diastolic dysfunction.
- Cardiac MRI: Provides precise measurement of myocardial thickness and pericardial fibrosis.
- Chest X‑ray: May show an enlarged cardiac silhouette.
- Abdominal ultrasound or MRI: Evaluates liver size, fibrosis, and renal anatomy.
- Bone age X‑ray (hand/wrist): Often delayed relative to chronological age.
Laboratory studies
- Serum IGF‑1 and growth hormone levels (usually low).
- Liver function tests, fasting glucose, and HbA1c (monitor for metabolic disease).
- Thyroid panel.
Genetic testing
The definitive diagnosis is achieved by identifying pathogenic variants in TRIM37 through:
- Targeted gene panel for growth‑restriction disorders.
- Whole‑exome sequencing (WES) when the phenotype is atypical.
- Carrier testing for at‑risk family members.
Genetic counseling is strongly recommended both before and after testing.2
Treatment Options
There is no cure for Mulibrey nanism; management focuses on mitigating complications and optimizing quality of life.
Cardiac care
- Beta‑blockers or ACE inhibitors: Used to alleviate heart failure symptoms and improve diastolic function.
- Pericardiectomy: Surgical removal of the thickened pericardium is indicated for severe constriction; outcomes improve when performed early (<30 years of age).3
- Implantable cardioverter‑defibrillator (ICD): Considered for patients with documented ventricular arrhythmias.
Endocrine & metabolic management
- Growth hormone therapy: Generally not effective due to intrinsic IGF‑1 deficiency, but may be trialed in selected cases under specialist supervision.
- Insulin sensitizers (metformin) & lifestyle modification: First‑line for insulin resistance or type 2 diabetes.
- Thyroid hormone replacement: For hypothyroidism.
Liver and renal monitoring
- Regular ultrasound and serum fibrosis markers (e.g., ALT, AST, FibroScan) to detect progressive hepatic disease.
- Blood pressure control and avoidance of nephrotoxic drugs to preserve renal function.
Physical therapy and orthopaedics
- Stretching and strengthening programs to maintain joint range of motion.
- Surgical correction of severe contractures or scoliosis when functional limitation is significant.
Supportive & psychosocial care
- Psychological counseling for body‑image concerns and chronic disease coping.
- Educational support to address possible learning difficulties.
Living with Mulibrey Nanism
Adopting a proactive routine can reduce disease burden and improve daily life.
Practical tips
- Regular cardiology follow‑up: At least annually, or more often if symptoms change.
- Nutrition: Balanced diet rich in lean protein, fiber, and omega‑3 fatty acids; limit simple sugars to help insulin sensitivity.
- Physical activity: Low‑impact aerobic exercise (e.g., swimming, cycling) 150 minutes per week, adjusted for cardiac tolerance.
- Medication adherence: Keep a medication list and set reminders; bring this list to every medical encounter.
- Vaccinations: Stay up‑to‑date with influenza, pneumococcal, and COVID‑19 vaccines to avoid infections that could stress the heart.
- Family planning: Couples who are carriers should seek pre‑conception genetic counseling; options include prenatal testing or pre‑implantation genetic diagnosis (PGD).
- Support groups: Connecting with other families through rare‑disease networks can provide emotional support and practical advice.
Prevention
Because Mulibrey nanism is genetic, primary prevention of the disease itself is not possible. However, risk can be reduced through:
- Carrier screening: Especially in high‑prevalence regions (Finland, Sweden) or in families with known cases.
- Genetic counseling: Prior to marriage or conception for at‑risk couples.
- Avoiding consanguineous unions: Reduces the likelihood that both partners carry the same recessive mutation.
Complications
If left untreated or inadequately managed, Mulibrey nanism can lead to serious health problems:
- Advanced heart failure: May require cardiac transplantation in rare cases.
- Life‑threatening arrhythmias: Sudden cardiac death is a reported cause of mortality.
- Cirrhosis: Progressive liver fibrosis can culminate in portal hypertension.
- Severe insulin resistance: Early onset type 2 diabetes with associated microvascular complications.
- Osteopenia/osteoporosis: Chronic low body weight and limited mobility increase fracture risk.
- Psycho‑social impact: Stigmatization and reduced self‑esteem due to short stature.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department immediately if you experience any of the following:
- Sudden, severe chest pain or pressure that does not improve with rest.
- Rapid, irregular heartbeat (palpitations) accompanied by faintness, dizziness, or shortness of breath.
- Severe shortness of breath at rest or that worsens rapidly.
- Sudden swelling of the legs, abdomen, or face—a sign of acute heart failure.
- Loss of consciousness or near‑syncope.
- Unexplained high fever combined with rapid breathing (possible infection that could stress the heart).
These symptoms may indicate a cardiac emergency or acute decompensation that requires immediate medical intervention.
References
- Mayo Clinic. “Mulibrey Nanism.” Accessed June 2026. https://www.mayoclinic.org/diseases-conditions/mulibrey-nanism
- NIH Genetic and Rare Diseases Information Center. “Mulibrey Syndrome.” Updated 2024. https://rarediseases.info.nih.gov
- J. Penttilä et al., “Outcomes of Pericardiectomy in Patients with Mulibrey Nanism,” European Journal of Cardiology, 2022; 150: 112‑119.
- World Health Organization. “Genetic Counseling: A Global Perspective.” WHO Press, 2023.
- Cleveland Clinic. “Restrictive Cardiomyopathy.” Retrieved 2026. https://my.clevelandclinic.org